Preclinical studies have demonstrated that the inhibition of Bcl-XL and/or MCL-1 exhibits significant anti-AML activity and enhances the sensitivity of venetoclax in AML treatment (Carter et al., 2020; Vanna et al., 2020). Here, MCL1 is linked to acute myeloid leukemia.